Business Update
Colazal pediatric exclusivity granted for bowel disease
Published in Medical Letter on the CDC and FDA, October 1st, 2006
The exclusivity is based upon the FDA's acceptance of the clinical package the company submitted on June 20, 2006 in response to a written request received from the U.S. Food and Drug Administration for clinical information about the safe and effective use of Colazal in pediatric patients between 5 and 17 years of age with ulcerative colitis.
The FDA has informed Salix that the new marketing exclusivity expiration date for Colazal will be posted in the Electronic Orange Book (EOB) at the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Antimicrobial Resistance
Carbapenem resistance in Klebsiella is not detected by susceptibility testing - Food Safety
Infections associated with cantaloupe are growing public health concern - Meningitis Risk Factors
Invasive Enterobacter sakazakii disease in infants was examined - Meningitis Vaccine
Hib conjugate vaccine was effective in children in Kenya - Occupational Exposure
Workplace conditions frequently exacerbate asthma - Addiction Medicine
Drug treatment programs reduce criminal behavior - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
